Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Enfuvirtide
Drug ID BADD_D00771
Description Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Indications and Usage Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
Marketing Status Prescription
ATC Code J05AX07
DrugBank ID DB00109
KEGG ID D02499
MeSH ID D000077560
PubChem ID 16130199
TTD Drug ID D06GBQ
NDC Product Code 12869-380; 0004-0381
Synonyms Enfuvirtide | Pentafuside | DP 178 | DP178 | DP-178 | Fuzeon | T20 Peptide | Peptide T20 | T20, Peptide
Chemical Information
Molecular Formula C204H301N51O64
CAS Registry Number 159519-65-0
SMILES CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC (=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C C(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC (CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC 1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43) C(=O)NC(CC(=O)N)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC7=CC=CC=C7)C(=O)N)NC(=O)C(C C(C)C)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CO)NC( =O)C(C(C)O)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disability26.01.01.003--Not Available
Discomfort08.01.08.003--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Ear disorder04.03.01.001--Not Available
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.001--Not Available
Eosinophilia01.02.04.001--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Folliculitis23.09.04.007; 11.01.12.018--
Gamma-glutamyltransferase increased13.03.01.011--
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glomerulonephritis20.05.01.001; 10.02.01.006--Not Available
Guillain-Barre syndrome17.09.01.001; 11.07.01.001; 10.04.10.005--
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Headache17.14.01.001--
Hepatic steatosis14.08.04.005; 09.01.07.003--Not Available
Hepatitis toxic12.03.01.016; 09.01.07.017--Not Available
Herpes simplex11.05.02.001; 23.09.03.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages